ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,596.80
0.36%
S&P ASX All Technology
2,978.80
0.34%
Brent Oil
83.975
0.52%
US Dollar vs AUD
1.52991
-0.07%
Bitcoin
57,362.81
-1.50%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ionis Pharmaceuticals Inc (IONS)

  7. Ionis Pharmaceuticals Inc (IONS) News

IONS

Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IONS
DateTimeSourceHeadlineSymbolCompany
25/04/202421:00PR Newswire (US)Ionis Publishes 2023 Corporate Responsibility ReportNASDAQ:IONSIonis Pharmaceuticals Inc
23/04/202421:05PR Newswire (US)Ionis to hold first quarter 2024 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
07/04/202423:48PR Newswire (US)Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
01/04/202422:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
28/03/202422:05PR Newswire (US)Ionis to hold olezarsen Phase 3 data webcastNASDAQ:IONSIonis Pharmaceuticals Inc
25/03/202423:18PR Newswire (US)Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meetingNASDAQ:IONSIonis Pharmaceuticals Inc
13/03/202422:00PR Newswire (US)Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASHNASDAQ:IONSIonis Pharmaceuticals Inc
06/03/202423:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202411:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202411:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202411:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202411:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
05/03/202411:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
01/03/202401:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
01/03/202401:05PR Newswire (US)Ionis announces new chief global product strategy officer to lead next phase of commercial growthNASDAQ:IONSIonis Pharmaceuticals Inc
28/02/202423:05PR Newswire (US)Ionis to present at upcoming investor conferencesNASDAQ:IONSIonis Pharmaceuticals Inc
22/02/202403:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202423:00PR Newswire (US)Ionis reports fourth quarter and full year 2023 financial resultsNASDAQ:IONSIonis Pharmaceuticals Inc
21/02/202402:39Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
17/02/202411:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
17/02/202408:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
15/02/202423:00PR Newswire (US)Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndromeNASDAQ:IONSIonis Pharmaceuticals Inc
15/02/202402:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IONSIonis Pharmaceuticals Inc
13/02/202422:09Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IONSIonis Pharmaceuticals Inc
08/02/202423:00PR Newswire (US)Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathyNASDAQ:IONSIonis Pharmaceuticals Inc
07/02/202423:05PR Newswire (US)Ionis to hold fourth quarter and full year 2023 financial results webcastNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202411:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202411:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202411:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
03/02/202411:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IONSIonis Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IONS

Your Recent History

ASX
BHP
BHP
ASX
WDC
Westfield
CCOM
SILVER
SILVER
FX
EURAUD
Euro vs AUD
FX
GBPAUD
Sterling vs AUD
FTSE
UKX
FTSE 100
PM
XAUUSD
Gold vs US Dollar
FX
AUDCAD
AUD vs CAD
ASX
XAO
Australian SE All Ordina...
ASX
CSL
CSL
COIN
BTCUSD
Bitcoin
ASX
RIO
Rio Tinto
FX
AUDJPY
AUD vs Yen
NYSE
KO
Coca Cola
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved